C17orf77 Inhibitors

C17orf77 Kinase inhibitors such as Staurosporine and U0126 are selected based on the common regulatory mechanism of protein phosphorylation, which is a widespread method of controlling protein function. Inhibition of kinases can, therefore, have far-reaching impacts on protein function and interaction networks. LY294002 and Rapamycin are chosen for their roles in inhibiting critical signaling pathways like PI3K/AKT and mTOR, respectively. These pathways are integral to processes such as cell growth, survival, and metabolism, and their inhibitors can broadly affect protein function within these pathways.

Proteasome inhibitors, Bortezomib and MG132, are included on the premise that the ubiquitin-proteasome system plays a critical role in protein degradation. By preventing protein degradation, these inhibitors can lead to an increase in the cellular levels of numerous proteins, potentially including C17orf77. The selection of these inhibitors is based on the principle of preventing the turnover of cellular proteins, hence possibly affecting the levels of C17orf77 indirectly.